MedTrace Logo

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

NCT03610230 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-10-06

No results posted yet for this study

Summary

1. To compare patient-reported satisfaction, efficacy and short-term safety profile of Monofer® in a single bolus dose with Venofer® in split doses in the treatment of absolute or functional iron deficiency anemia in patients on PD.
2. To compare patient symptomatology on fatigue after treatment of Monofer® compared with Venofer® .

Conditions

  • Iron Deficiency Anemia Treatment

Interventions

DRUG

Iron Isomaltoside

Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron

DRUG

Iron sucrose

the currently most widely used intravenous iron preparation with good safety profile

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Maggie Ming Yee Mok, MBBS FHKAM · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2021-03-30
Completion
2021-03-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03610230 on ClinicalTrials.gov